Experts discuss the criteria used to define LS-SCLC, recent evidence and guideline changes in management, the appropriate use of immunotherapy, and differentiating treatment-related toxicities from disease progression. For the complete activity, including supporting material, please visit: www.peervoice.com/ZCX861. Presented by: Laura Ruth Alder, MD, Puneeth Iyengar, MD, PhD, and Pooja Karukonda, MD. Learning Objectives: Describe the clinical and radiographic criteria used to define limited-stage small cell lung cancer (LS-SCLC) and common pitfalls encountered in real-world practice; Summarize recent evidence and guideline changes in LS-SCLC management, including subgroup-specific considerations; Integrate patient response, treatment regimen, and multidisciplinary input to determine eligibility, timing, and duration of consolidation immunotherapy in real-world LS-SCLC care; and Describe strategies for differentiating disease progression versus treatment-associated pneumonitis in patients receiving immunotherapy for LS-SCLC and implications for anti-cancer treatment decisions.